Fusing Structural Phenotypes with Functional Data for Early Prediction of Primary Angle Closure Glaucoma Progression
Authors:
Swati Sharma,
Thanadet Chuangsuwanich,
Royston K. Y. Tan,
Shimna C. Prasad,
Tin A. Tun,
Shamira A. Perera,
Martin L. Buist,
Tin Aung,
Monisha E. Nongpiur,
Michaël J. A. Girard
Abstract:
Purpose: To classify eyes as slow or fast glaucoma progressors in patients with primary angle closure glaucoma (PACG) using an integrated approach combining optic nerve head (ONH) structural features and sector-based visual field (VF) functional parameters. Methods: PACG patients with >5 reliable VF tests over >5 years were included. Progression was assessed in Zeiss Forum, with baseline VF within…
▽ More
Purpose: To classify eyes as slow or fast glaucoma progressors in patients with primary angle closure glaucoma (PACG) using an integrated approach combining optic nerve head (ONH) structural features and sector-based visual field (VF) functional parameters. Methods: PACG patients with >5 reliable VF tests over >5 years were included. Progression was assessed in Zeiss Forum, with baseline VF within six months of OCT. Fast progression was VFI decline <-2.0% per year; slow progression >-2.0% per year. OCT volumes were AI-segmented to extract 31 ONH parameters. The Glaucoma Hemifield Test defined five regions per hemifield, aligned with RNFL distribution. Mean sensitivity per region was combined with structural parameters to train ML classifiers. Multiple models were tested, and SHAP identified key predictors. Main outcome measures: Classification of slow versus fast progressors using combined structural and functional data. Results: We analyzed 451 eyes from 299 patients. Mean VFI progression was -0.92% per year; 369 eyes progressed slowly and 82 rapidly. The Random Forest model combining structural and functional features achieved the best performance (AUC = 0.87, 2000 Monte Carlo iterations). SHAP identified six key predictors: inferior MRW, inferior and inferior-temporal RNFL thickness, nasal-temporal LC curvature, superior nasal VF sensitivity, and inferior RNFL and GCL+IPL thickness. Models using only structural or functional features performed worse with AUC of 0.82 and 0.78, respectively. Conclusions: Combining ONH structural and VF functional parameters significantly improves classification of progression risk in PACG. Inferior ONH features, MRW and RNFL thickness, were the most predictive, highlighting the critical role of ONH morphology in monitoring disease progression.
△ Less
Submitted 19 August, 2025;
originally announced August 2025.
Reinforcement Learning for Personalized Drug Discovery and Design for Complex Diseases: A Systems Pharmacology Perspective
Authors:
Ryan K. Tan,
Yang Liu,
Lei Xie
Abstract:
Many multi-genic systemic diseases such as neurological disorders, inflammatory diseases, and the majority of cancers do not have effective treatments yet. Reinforcement learning powered systems pharmacology is a potentially effective approach to design personalized therapies for untreatable complex diseases. In this survey, state-of-the-art reinforcement learning methods and their latest applicat…
▽ More
Many multi-genic systemic diseases such as neurological disorders, inflammatory diseases, and the majority of cancers do not have effective treatments yet. Reinforcement learning powered systems pharmacology is a potentially effective approach to design personalized therapies for untreatable complex diseases. In this survey, state-of-the-art reinforcement learning methods and their latest applications to drug design are reviewed. The challenges on harnessing reinforcement learning for systems pharmacology and personalized medicine are discussed. Potential solutions to overcome the challenges are proposed. In spite of successful application of advanced reinforcement learning techniques to target-based drug discovery, new reinforcement learning strategies are needed to address systems pharmacology-oriented personalized de novo drug design.
△ Less
Submitted 23 February, 2022; v1 submitted 21 January, 2022;
originally announced January 2022.
